Inhalation drug delivery involves administering drugs to the lungs through the mouth (pulmonary route) or nose (intranasal route), enabling them to bypass the blood-brain barrier. Small molecules have been the focus for inhalation delivery, but recent developments and an increased interest in inhalable COVID-19 vaccines have led to a shift toward inhalable biologics for conditions where injection delivery is the norm.
• What are the innovative methods for formulating inhalable biologics?
• What does the pipeline analysis for inhalable vaccines and monoclonal antibodies look like?
• What are the funding evaluations, patent evaluations, regulatory environments, and developments for partnerships and collaborations for inhalable biologics?
• What are the growth opportunities for technology developers in the inhalable biologics space?
Sign up for a complimentary Growth Pipeline Dialog™
A Growth Pipeline Dialog is a structured open discussion with our growth experts providing unparalleled industry intelligence, technology advancements, and proven implementation best practices. This discussion will spark innovative thinking and help generate a pipeline of growth opportunities you can leverage to maximize your company’s future growth potential.